Company / PP&E (Net)
Arrowhead Pharmaceuticals PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$382.5M
FY2025
5-year range
$48.7M / $386.0M
FY2021-FY2025
Trend
-0.9%
vs FY2024
Sector context
#23 of 193
Health Care
What the data says
Arrowhead Pharmaceuticals's pp&e (net) of $383M is higher than 88% of companies in the Health Care sector (FY2025). PP&E (Net) has fluctuated over the past 10 years, ranging from $14M in FY2018 to $386M in FY2024.
Based on SEC 10-K filings.
$383M in FY2025 with a 5-year CAGR of +65.4%. Top quartile in the Health Care sector.
Improved from $290M to $383M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +51.4%
- 5-Year CAGR
- +65.4%
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 193This company $382.5M Sector average $777.6M
▼
-50.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +65.4%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 0.9% year-over-year.
- Ranks #23 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $382.5M | -0.9% |
| FY2024 | $386.0M | +33.0% |
| FY2023 | $290.3M | +163.2% |
| FY2022 | $110.3M | +126.6% |
| FY2021 | $48.7M | +57.6% |
| FY2020 | $30.9M | +33.0% |
| FY2019 | $23.2M | +66.6% |
| FY2018 | $13.9M | -10.2% |
| FY2017 | $15.5M | +0.8% |
| FY2016 | $15.4M | +239.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026